Partner for Impact
How Ecraid is Accelerating Infectious Disease and AMR Research with Innovative Trial Design and a 'Warm-base' European Network
Infectious Diseases (ID) and Antimicrobial Resistance (AMR) represent a continuous, fast-moving threat to global health and economies. For industry partners and regulatory bodies, clinical research in this domain requires more than just speed - it demands innovation, collaboration, and seamless execution to efficiently generate the evidence needed to inform patient care.
Ecraid is dedicated to tackling these critical challenges through its unique, full-service model and ongoing studies. We are now amplifying this message with the launch of our new campaign, “Partner for Impact”. This campaign showcases our proven approach, which is designed to help our partners run more impactful studies. By uniting Europe’s premier academic clinical research network with cutting-edge trial methodologies, Ecraid accelerates evidence generation while simultaneously reducing investment requirements and maximising scientific and clinical impact.
Partner with Ecraid to accelerate your ID and AMR research.
Together, we are shaping the future of research.
The Power of Innovative Trial Design: Embracing Adaptive Platform Trials
Traditional clinical trials are often too rigid and slow to respond effectively to fast-moving infectious threats. Ecraid is championing a necessary evolution by focusing on innovative study designs, particularly Adaptive Platform Trials (APTs), which we believe are the future of ID and AMR research.
This design is a powerful, flexible alternative to traditional models. APTs allow for continuous enrolment, simultaneous testing of multiple interventions, and real-time adjustments based on emerging data, leading to faster and more efficient research conclusions.
Ecraid's Expertise and Impact
The SARS-CoV-2 pandemic demonstrated the immense value of APTs. Groundbreaking trials supported by Ecraid, like REMAP-CAP, rapidly evaluated over 60 interventions, yielding 16 conclusions that directly impacted patient care. This showcases their ability to deliver critical insights during dynamic health crises.
For industry and regulators, APTs can answer more research questions with fewer resources, reduce the time to results, and ethically optimise patient care by increasing the likelihood of participants receiving the most beneficial treatments. This translates to increased efficiencies for all stakeholders.
The Efficiency of a Permanent, Warm-base Network
Trial delays don't just cost money - they slow down access to treatments that matter. One of the biggest hurdles is poor site selection, which can cause up to 40% of trial delays.
Ecraid eliminates this bottleneck by operating on the concept of a ‘warm-base’ network: a novel approach that significantly increases the speed, efficiency, and quality of trials.
The Ecraid Operational Advantage
Our network is a permanent infrastructure comprising over 1,200 engaged sites across 42 European countries. These sites are actively recruiting patients on a continuous basis, replacing the ad hoc, temporary collaborations that lead to long set-up times and suboptimal outcomes.
This network is supported by a central coordinating team that uses its deep knowledge of each site’s capabilities and experience to match every study with the sites that best fit its needs. Furthermore, we combine this operational insight with access to epidemiological data on AMR and healthcare-associated infections across Europe, ensuring truly smart site selection.
The result for our partners is clear: reduced delays, increased efficiency, and high-quality clinical trials.
We ensure that efficiency and quality are never a trade-off.
Partner for Impact
By leveraging our established infrastructure, cutting-edge trial methodologies, and access to key academic opinion leaders in the field of infectious diseases, Ecraid offers our partners end-to-end support.
We provide a seamless path from study design to delivery, ensuring the generation of high-quality research with rigorous quality assurance, high operational efficiency, and impecable scientific integrity. This full-service model enables our partners to stay ahead of the market while advancing treatments for patients.
Check out the full campaign details and our essential resources.